The breakpoint cluster region/Abelson leukemia virus (BCR-ABL) inhibitors have been used to treat chronic myeloid leukemia (CML), acute lymphocytic leukemia (ALL), and other hematological malignancies. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.